Permanent product Record

ALPHA LION

SUPERHUMAN Extreme

CURRENTRecord last observed August 3, 2026very-high-stim

Alpha Lion SUPERHUMAN Extreme has a current Record. Last observed August 3, 2026. The current public formula contains 19 declared ingredient lines. Comparable formula history is not yet available.

Current Record

The current declared formula.

Printed label wording stays separate from FormulaSignal's normalized identity. Current formula observed August 3, 2026.

Serving size
Not recorded
Servings
Not recorded
Caffeine
376 mg per serving
Formula scope
PRODUCT WIDE
Alpha Lion SUPERHUMAN Extreme, current declared formula observed August 3, 2026. Each row gives the printed label wording, the declared amount, and FormulaSignal's normalized identity.
Original label wordingDeclared amountNormalized identity
Niacin (from Inositol Hexanicotinate)12 mg NEniacin from inositol hexanicotinate
Vitamin B6 (as Pyridoxine HCl)28 mgvitamin b6
Vitamin B12 (as Methylcobalamin)500 mcgvitamin b12
Choline (from Choline L (+) Bitartrate)200 mgcholine from choline l bitartrate
L-Citrulline6000 mgl-citrulline
Beta Alanine3200 mgbeta-alanine
Betaine Anhydrous2500 mgbetaine anhydrous
L-Tyrosine2000 mgl-tyrosine
Agmatine Sulfate1000 mgagmatine sulfate
Vitacholine Choline L (+) Bitartrate500 mgcholine bitartrate
Caffeine Anhydrous340 mgcaffeine
zumXR Extended Release Caffeine (yielding 25mg caffeine)34 mgzumxr caffeine material
zumXR Delayed Release Caffeine (yielding 11mg caffeine)14 mgzumxr caffeine material
Bitter Orange Extract (min. 25% p-Synephrine) (Citrus aurantium)(Fruit)120 mgbitter orange extract min. 25% p-synephrine citrus aurantium fruit
Ivy Extract (std. 10% Hederacosides)(Hedera helix)(Leaf)100 mgivy extract std. 10% hederacosides hedera helix leaf
Huperzia Serrata Extract (1% Huperzine-A) (Aerial Parts)20 mghuperzia serrata extract 1% huperzine-a aerial parts
Vincamine10 mgvincamine
Black Pepper Extract (95% piperine)(Piper nigrum)(Fruit)10 mgblack pepper extract
Alfabin Rauwolscine 90% (Alpha-Yohimbine) (Rauwolfia vomitoria)(Root)1 mgalfabin rauwolscine 90% alpha-yohimbine rauwolfia vomitoria root

Serving economics

Facts and calculations stay labeled.

Captured commercial fact
Observed price, basis not established: $49.99
Price observation
August 3, 2026
Captured commercial serving count
21 servings per container
Deterministic calculation
$49.99 ÷ 21 = $2.38 per serving

Historical timeline

Comparable formula states.

Dates below are observation dates. They are not exact reformulation dates.

Historical formula evidence is not yet sufficient for a reliable comparison. This does not establish that the product never changed.

Confirmed Signals

Reviewed changes in the public Record.

No confirmed public Signal is associated with this product. This is not a claim that the product never changed.

Research-dose context

Selected evidence, not a universal effective dose.

These comparisons retain the studied protocol, source, and limitations. They do not establish safety, effectiveness, or a dose recommendation for this product.

A1

L-citrulline

Product declaration
L-Citrulline: 6000 mg
Selected studied range
3000 to 9000 mg
Protocol and duration
per day, in the studies NIH ODS summarizes
Studied context
Studied as a nitric-oxide pathway precursor (converted to arginine via the urea cycle) for aerobic exercise performance measures such as oxygen-uptake (VO2) kinetics, blood lactate, and rate of perceived exertion, and for acute resistance-exercise performance and muscle oxygenation. NIH ODS describes evidence for enhancing performance as limited, with few studies and conflicting results.
Limitations
A 2022 systematic review/meta-analysis found no significant benefit for endurance-performance outcomes specifically. A single 8 g acute dose did not enhance isometric force production, muscle endurance, or muscle-oxygenation parameters in one resistance-exercise study. NIH ODS characterizes overall performance-enhancement evidence as limited.

Selected evidence: NIH ODS, Dietary Supplements for Exercise and Athletic Performance · Open source

A2

Beta-alanine

Product declaration
Beta Alanine: 3200 mg
Selected studied range
4000 to 6000 mg
Protocol and duration
per day in divided doses, for at least 2 to 4 weeks, not as a single pre-workout dose
Studied context
Studied for high-intensity exercise capacity in the 60-240 second range via elevation of muscle carnosine, which acts as an intracellular pH buffer against acidosis. ISSN 2015 position stand: greatest performance benefits in "open end-point" tasks/time trials lasting 1-4 minutes; some benefit noted in aerobic exercise up to roughly 25 minutes; attenuation of neuromuscular fatigue, particularly noted in older adults.
Limitations
Strength/resistance-training outcomes remain mixed; training volume may increase without a clear strength gain. Tasks under 60 seconds do not show benefit. Endurance benefit beyond about 25 minutes is not established. Long-term safety data beyond roughly a year, and effects in special/tactical populations, are flagged as needing more research.

Selected evidence: ISSN position stand on beta-alanine, 2015 · Open source

A1

Betaine anhydrous

Product declaration
Betaine Anhydrous: 2500 mg
Selected studied range
2000 to 5000 mg
Protocol and duration
per day, studied for up to 15 days
Studied context
NIH ODS describes betaine as studied for strength- and power-based performance in bodybuilders and cyclists, with "potential but modest" improvements from a limited set of small, sometimes conflicting studies. A 2024/2025 systematic review focused specifically on endurance performance (VO2max, time-to-exhaustion, time-to-completion, power output).
Limitations
The endurance systematic review explicitly states "limited and inconclusive evidence regarding the definitive ergogenic effect of betaine supplementation on endurance exercise performance". Only 2 of 5 reviewed studies showed a significant improvement, and the authors call for "additional, more rigorous research."

Selected evidence: NIH ODS, Dietary Supplements for Exercise and Athletic Performance · Open source

A2

L-tyrosine

Product declaration
L-Tyrosine: 2000 mg
Selected studied range
2000 to 2000 mg
Protocol and duration
per day for five days, in the cadet study
Studied context
Studied as the dietary precursor to norepinephrine for mitigating cognitive performance decrements under acute stress. A 2015 Military Medicine evidence review (rapid evidence assessment, 14 trials: 10 RCTs + 4 controlled clinical trials) issued a "weak recommendation" in favor of tyrosine for cognitive stress specifically, stating "all studies showed a positive effect" on that outcome. A widely cited primary study (Deijen et al. 1999, Brain Research Bulletin) gave cadets 2 g tyrosine daily for five days during a combat training course and found better memory and tracking-task performance, plus lower systolic blood pressure, versus a carbohydrate control.
Limitations
The 2015 Military Medicine review states explicitly that "no recommendation could be made" for tyrosine's effect on physical performance under stressful physical conditions, and concludes "available evidence is insufficient to make confident recommendations on the effectiveness of tyrosine for mitigating stress effects on physical/cognitive performance" overall, despite the positive signal on cognition. A separate heat-stress study found tyrosine ingestion did not influence cognitive function or physical performance during exercise heat stress despite raised serum tyrosine. NIH ODS's exercise/athletic-performance fact sheet does not cover tyrosine at all.

Selected evidence: Deijen et al., Brain Research Bulletin, 1999

A2

Agmatine sulfate

Product declaration
Agmatine Sulfate: 1000 mg
Selected studied range
No dose range selected
Protocol and duration
Not recorded in the selected comparison
Studied context
Human data is comparatively sparse. A randomized double-blind placebo-controlled trial studied oral agmatine sulfate (1,335-3,560 mg/day for up to 3 weeks) for lumbar disc-associated radiculopathy (a clinical/pain context, not sports performance). A 2019 Scientific Reports paper examined safety and neurochemical profiles of acute and sub-chronic oral agmatine sulfate treatment.
Limitations
Sports-performance-specific human efficacy data for agmatine sulfate (e.g., a dedicated ISSN position stand) was not located in this research pass. Evidence located centers on safety/tolerability and non-sports clinical contexts rather than an authoritative performance-outcome verdict. Long-term safety in larger populations remains an open gap per the safety literature reviewed.

Selected evidence: Safety and neurochemical profiles of oral agmatine sulfate, 2019 · Open source

A1

Choline bitartrate

Product declaration
Vitacholine Choline L (+) Bitartrate: 500 mg
Selected studied range
425 to 550 mg
Protocol and duration
Adequate Intake for adults, a nutrient reference and not an ergogenic dose
Studied context
NIH ODS's Choline Health Professional fact sheet establishes choline's core physiological roles: synthesis of phosphatidylcholine and sphingomyelin for cell-membrane structure, acetylcholine (a neurotransmitter for memory, mood, and muscle control) production, methyl-group donation, gene-expression modulation, and brain development. Choline bitartrate is named as one of three supplement forms (with phosphatidylcholine and lecithin).
Limitations
NIH ODS states explicitly: "No studies have compared the relative bioavailability of choline from these different forms". Meaning choline bitartrate's absorption/efficacy relative to phosphatidylcholine, lecithin, or non-bitartrate forms (like alpha-GPC) is not established by NIH's own review.

Selected evidence: NIH ODS, Choline fact sheet · Open source

A2

Vincamine

Product declaration
Vincamine: 10 mg
Selected studied range
No dose range selected
Protocol and duration
Not recorded in the selected comparison
Studied context
Vincamine has been studied as a pharmacologically active alkaloid in older human clinical and pharmacokinetic research. Those studies are not pre-workout efficacy studies and do not establish a dietary-supplement dose range.
Limitations
The product label does not establish pharmaceutical formulation, purity, or equivalence to the preparations in the older studies. No sports-performance benefit is established by the cited sources.

Selected evidence: Severe ventricular arrhythmia following parenteral administration of vincamine · Open source

A2

Caffeine

Product declaration
Total caffeine from all declared sources: 376 mg
Selected studied range
140 to 420 mg
Protocol and duration
2 to 6 mg per kg body mass, 15 to 60 minutes before exercise, shown here for a 70 kg adult
Studied context
Studied for endurance-type aerobic exercise (moderate to large ergogenic effect, most consistent evidence category per ISSN 2021), muscular endurance and movement velocity in resistance exercise (small to moderate effects), sprinting/jumping/throwing (2-7% improvements), and cognitive attention/vigilance under fatigue. NIH ODS notes it "might enhance performance in endurance-type activities... And intermittent, long-duration activities."
Limitations
Minimal effective dose remains unclear. Repeated-sprint performance benefit is inconsistent and the ISSN position stand says this "requires further research." Effects of habitual/chronic caffeine use on the ergogenic response are described as equivocal.

Selected evidence: ISSN position stand on caffeine and exercise performance, 2021, with NIH ODS · Open source

Cautions and regulatory records

A filing and a documented risk are not the same thing.

These attach to declared ingredients, not to this product as a whole. Nothing here establishes that the product is safe or unsafe. Talk with a qualified health professional.

Documented cautions on declared ingredients

  • SAFETY ADVISORY · A1

    Stimulant-load gate. The current record declares 376 mg of caffeine per serving, which triggers FormulaSignal's 300 mg stimulant-load gate. That 300 mg is our own screening threshold, not a regulatory limit. We set it there because NIH ODS summarizes an FDA reference point of 400 mg per day for healthy adults, so a single serving at 300 mg uses three quarters of that daily figure before any coffee, tea, or soda is counted. The gate flags that headroom is small. It is not a finding that the product is unsafe, and individual responses vary.

    Dietary Supplements for Exercise and Athletic Performance, NIH Office of Dietary Supplements · Open source

  • SAFETY ADVISORY · A2

    Vincamine. Published case reports describe severe ventricular arrhythmias after parenteral vincamine administration. Keep this as a safety advisory with route and formulation limits; do not state that the covered product caused or will cause those events.

    Severe ventricular arrhythmia following parenteral administration of vincamine, PubMed · Open source

Where the sources disagree

What we could not read cleanly.

A disagreement between sources is recorded rather than smoothed into one confident number. None of these is a Signal.

No source conflict is recorded on this Record. That is not a claim that every source agrees, only that none we read disagreed.

Evidence

Audit the material claims.

  • Alpha Lion

    P1 current formula source · observed August 3, 2026 · accessed August 3, 2026

    Open source evidence
  • Alpha Lion

    P1 commercial capture · observed August 3, 2026 · accessed August 3, 2026

    Open source evidence

Go deeper

Ask now, or keep watch.

No released consumer report is available for this product. Browse Reports.